Table 2.

Preliminary outcomes of the pilot randomized controlled trial of ARTEMIS+CM (N = 21)

	ARTEMIS+CM (N = 12) M (SD)	CM-only (N = 9) M (SD)
Positive affect
Baseline	30.3 (9.9)	30.3 (7.3)
2 Months	34.8 (9.2)*	32.8 (7.7)
3 Months	34.1 (7.4)	35.4 (8.1)
6 Months	32.0 (7.9)	33.3 (8.9)
Negative affect
Baseline	17.7 (6.2)	20.8 (8.3)
2 Months	14.8 (9.1)	12.8 (8.6)*
3 Months	16.5 (7.5)	15.0 (4.5)
6 Months	17.3 (8.8)	15.1 (8.8)
Total number of risky anal sex partners
Baseline	0.1 (0.3)	0.2 (0.7)
3 Months	0.2 (0.4)	1.3 (3.5)
6 Months	0.0 (0.0)	0.0 (0.0)
Number of risky anal sex partners on methamphetamine
Baseline	0.0 (0.0)	0.2 (0.7)
3 Months	0.1 (0.3)	0.0 (0.0)
6 Months	0.0 (0.0)	0.0 (0.0)
Self-reported methamphetamine use (past 30 days)
Baseline	1.3 (1.7)	1.3 (3.0)
2 Months	2.4 (3.3)	2.3 (5.2)
3 Months	4.4 (7.5)	0.1 (0.4)
6 Months	4.3 (6.8)	0.1 (0.4)
	N (%)	N (%)
Reactive urine sample for stimulants
Baseline	1 (8.3)	1 (12.5)
2 Months	2 (22.2)	1 (12.5)
3 Months	3 (27.3)	0 (0.0)
6 Months	2 (20.0)	0 (0.0)

^*p<.05